Pharmaceutical Industry Veteran Dr. Craig Eagle Appointed as an Independent Member to Regenicin Board of Directors

Joins Amgen Co-Founder Dr. Joseph Rubinfeld as the second independent board member; Brings another authoritative voice to Regenicin's corporate governance body

NEW YORK, September 7, 2010 - Regenicin, Inc. (www.regenicin.com) (OTC Bulletin Board: WDSTD), a
clinical-stage biotechnology company, announced today that it has named Craig
Eagle, M.D. to its board of directors. Dr. Eagle currently serves as Vice
President of Strategic Alliances and Partnerships for the Oncology business
unit at Pfizer Inc. Dr. Eagle joins Amgen Co-Founder Dr. Joseph Rubinfeld as
the second independent member of Regenicin's board of directors.

Dr. Eagle brings a wealth of pharmaceutical industry experience to help
Regenicin further the commercialization efforts of PermaDerm(TM)
(www.regenicin.com/about-permaderm.html), its proprietary
tissue-engineered skin substitute intended to restore the qualities of
healthy human skin for use in the treatment of burns, chronic wounds and a
variety of plastic surgery procedures.

Dr. Eagle attended medical school at the University of New South Wales,
Sydney, Australia and received his general internist training at Royal North
Shore Hospital in Sydney. He completed his hemato-oncology and laboratory
hematology training at Royal Prince Alfred Hospital in Sydney. He was granted
Fellowship in the Royal Australasian College of Physicians (FRACP) and the
Royal College of Pathologists Australasia (FRCPA). After his training he
performed basic research at the Royal Prince of Wales Hospital to develop a
new monoclonal antibody to inhibit platelets. He joined Pfizer Australia in
2001 as part of the medical group. In Australia, his role involved leading
and participating in scientific research, regulatory and pricing &
re-imbursement negotiations for compounds in therapeutic areas including
oncology, anti-infectives, respiratory, arthritis and pain management.

In 2003, Pfizer relocated Dr. Eagle to the United States where he was
appointed as the worldwide lead for development of Celecoxib in oncology to
oversee the global research program. Since that time he has had increasing
responsibility for overseeing the global research plans and teams for
Irinotecan and Dalteparin. In 2007, he became head of the oncology
therapeutic area global medical group for Pfizer, including the US oncology
business. Dr. Eagle has led, or been directly involved with, teams that
resulted in eight new products or indications. As part of his current role at
Pfizer, he has led the integration of the Pfizer/Wyeth oncology businesses
and portfolio.

"We are very pleased to add Dr. Eagle as one of the independent members
of our board of directors," stated Randall McCoy, Regenicin, Chief Executive
Officer. "His wealth of experience in pharmaceutical product development will
be invaluable as we bring our PermaDerm(TM) product through the regulatory
process and into commercialization. We are confident that his extensive
experience in forming strategic alliances and partnerships will provide us
with critical guidance as we seek to maximize the commercialization potential
of PermaDerm(TM) in the future."

Commenting on his decision to join the board of directors at Regenicin,
Dr. Eagle stated: "It is extremely rare to find a company like Regenicin
which possesses the rights to a groundbreaking technology with the support of
such strong clinical data. When coupled with the production team at Lonza
behind them and hundreds of millions of development dollars already invested,
I am even more excited to be a part of assisting management down the final
stages of the path to commercialization. The ability to use a person's own
skin to grow additional skin for grafting eliminates almost all of the
problems inherent with other methods and will be critical towards saving and
substantially improving the lives of countless patients throughout the
world."

About Regenicin, Inc.

Regenicin, Inc. is a clinical-stage company developing next-generation
tissue-engineered skin substitutes to restore the qualities of healthy human
skin. Regenicin is a publicly traded company, with headquarters in New York,
NY. Additional information can be found in the company's filings with the
Securities and Exchange Commission located at www.sec.gov.

Jay Strell, Sunshine, Sachs and Associates, +1-212-691-2800, strell at sunshinesachs.com